Autoantibodies against type I IFNs in patients with life-threatening COVID-19

descriptionPublicationkeyboard_double_arrow_right Article 23 Oct 2020 Italy, United Kingdom, Netherlands, Turkey, France, Italy, Italy, Spain, Belgium, Spain, France, Belgium, France, Spain, Italy, France, France, Belgium, Italy, France, Italy, Italy, Norway, Australia, Denmark, France, Italy, France, France English Publisher:American Association for the Advancement of Science (AAAS)Journal:Science, volume 370 (issn: 0036-8075, eissn: 1095-9203,

Copyright policy )Funded by:EC | EASI-Genomics, NIH | NHGRI Genome Sequencing P..., NIH | Yale Center for Mendelian... +8 projects

Authors: Paul Bastard; Lindsey B. Rosen; Qian Zhang; Eleftherios Michailidis; Hans-Heinrich Hoffmann; Yu Zhang; Karim Dorgham; +193 Authors

Paul Bastard; Lindsey B. Rosen; Qian Zhang; Eleftherios Michailidis; Hans-Heinrich Hoffmann; Yu Zhang; Karim Dorgham; Quentin Philippot; Jérémie Rosain; Vivien Béziat; Jérémy Manry; Elana Shaw; Liis Haljasmägi; Pärt Peterson; Lazaro Lorenzo; Lucy Bizien; Sophie Trouillet-Assant; Kerry Dobbs; Adriana Almeida de Jesus; Alexandre Belot; Anne Kallaste; Emilie Catherinot; Yacine Tandjaoui-Lambiotte; Jeremie Le Pen; Gaspard Kerner; Benedetta Bigio; Yoann Seeleuthner; Rui Yang; Alexandre Bolze; András N. Spaan; Ottavia M. Delmonte; Michael S. Abers; Alessandro Aiuti; Giorgio Casari; Vito Lampasona; Lorenzo Piemonti; Fabio Ciceri; Kaya Bilguvar; Richard P. Lifton; Marc Vasse; David M. Smadja; Mélanie Migaud; Jérome Hadjadj; Benjamin Terrier; Darragh Duffy; Lluis Quintana-Murci; Diederik van de Beek; Lucie Roussel; Donald C. Vinh; Stuart G. Tangye; Filomeen Haerynck; David Dalmau; Javier Martinez-Picado; Petter Brodin; Michel C. Nussenzweig; Stéphanie Boisson-Dupuis; Carlos Rodríguez-Gallego; Guillaume Vogt; Trine H. Mogensen; Andrew J. Oler; Jingwen Gu; Peter D. Burbelo; Jeffrey I. Cohen; Andrea Biondi; Laura Rachele Bettini; Mariella D'Angio; Paolo Bonfanti; Patrick Rossignol; Julien Mayaux; Frédéric Rieux-Laucat; Eystein S. Husebye; Francesca Fusco; Matilde Valeria Ursini; Luisa Imberti; Alessandra Sottini; Simone Paghera; Eugenia Quiros-Roldan; Camillo Rossi; Riccardo Castagnoli; Daniela Montagna; Amelia Licari; Gian Luigi Marseglia; Xavier Duval; Jade Ghosn; John S. Tsang; Raphaela Goldbach-Mansky; Kai Kisand; Michail S. Lionakis; Anne Puel; Shen-Ying Zhang; Steven M. Holland; Guy Gorochov; Emmanuelle Jouanguy; Charles M. Rice; Aurélie Cobat; Luigi D. Notarangelo; Laurent Abel; Helen C. Su; Jean-Laurent Casanova; Andrés Augusto Arias; Bertrand Boisson; Soraya Boucherit; Jacinta Bustamante; Marwa Chbihi; Jie Chen; Maya Chrabieh; Tatiana Kochetkov; Tom Le Voyer; Dana Liu; Yelena Nemirovskaya; Masato Ogishi; Dominick Papandrea; Cécile Patissier; Franck Rapaport; Manon Roynard; Natasha Vladikine; Mark Woollett; Peng Zhang; Anuj Kashyap; Li Ding; Marita Bosticardo; Qinlu Wang; Sebastian Ochoa; Hui Liu; Samuel D. Chauvin; Michael Stack; Galina Koroleva; Neha Bansal; Clifton L. Dalgard; Andrew L. Snow; Jorge Abad; Sergio Aguilera-Albesa; Ozge Metin Akcan; Ilad Alavi Darazam; Juan C. Aldave; Miquel Alfonso Ramos; Seyed Alireza Nadji; Gulsum Alkan; Jerome Allardet-Servent; Luis M. Allende; Laia Alsina; Marie-Alexandra Alyanakian; Blanca Amador-Borrero; Zahir Amoura; Arnau Antolí; Sevket Arslan; Sophie Assant; Terese Auguet; Axelle Azot; Fanny Bajolle; Aurélie Baldolli; Maite Ballester; Hagit Baris Feldman; Benoit Barrou; Alexandra Beurton; Agurtzane Bilbao; Geraldine Blanchard-Rohner; Ignacio Blanco; Adeline Blandinières; Daniel Blazquez-Gamero; Marketa Bloomfield; Mireia Bolivar-Prados; Raphael Borie; Ahmed A. Bousfiha; Claire Bouvattier; Oksana Boyarchuk; Maria Rita P. Bueno; Jacinta Bustamante; Juan José Cáceres Agra; Semra Calimli; Ruggero Capra; Maria Carrabba; Carlos Casasnovas; Marion Caseris; Martin Castelle; Francesco Castelli; Martín Castillo de Vera; Mateus V. Castro; Emilie Catherinot; Martin Chalumeau; Bruno Charbit; Matthew P. Cheng; Père Clavé; Bonaventura Clotet; Anna Codina; Fatih Colkesen; Fatma Colkesen; Roger Colobran; Cloé Comarmond; Angelo G. Corsico; David Dalmau; David Ross Darley; Nicolas Dauby; Stéphane Dauger; Loic de Pontual; Amin Dehban; Geoffroy Delplancq; Alexandre Demoule; Antonio Di Sabatino; Jean-Luc Diehl;

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

- Summary
- Subjects
- Metrics

Abstract

The genetics underlying severe COVID-19 The immune system is complex and involves many genes, including those that encode cytokines known as interferons (IFNs). Individuals that lack specific IFNs can be more susceptible to infectious diseases. Furthermore, the autoantibody system dampens IFN response to prevent damage from pathogen-induced inflammation. Two studies now examine the likelihood that genetics affects the risk of severe coronavirus disease 2019 (COVID-19) through components of this system (see the Perspective by Beck and Aksentijevich). Q. Zhang et al. used a candidate gene approach and identified patients with severe COVID-19 who have mutations in genes involved in the regulation of type I and III IFN immunity. They found enrichment of these genes in patients and conclude that genetics may determine the clinical course of the infection. Bastard et al. identified individuals with high titers of neutralizing autoantibodies against type I IFN-α2 and IFN-ω in about 10% of patients with severe COVID-19 pneumonia. These autoantibodies were not found either in infected people who were asymptomatic or had milder phenotype or in healthy individuals. Together, these studies identify a means by which individuals at highest risk of life-threatening COVID-19 can be identified. Science , this issue p. eabd4570 , p. eabd4585 ; see also p. 404

Countries

Italy, United Kingdom, Netherlands, Turkey, France, Italy, Italy, Spain, Belgium, Spain, France, Belgium, France, Spain, Italy, France, France, Belgium, Italy, France, Italy, Italy, Norway, Australia, Denmark, France, Italy, France, France

Related Organizations

Université Libre de Bruxelles
Belgium
Université de Lorraine
France
Institut de Biologie François-JACOB
France
University of Amsterdam
Netherlands
Jean Monnet University
France

View all View all

Keywords

Male, COVID19, 32 Biomedical and Clinical Sciences, DISEASE, Coronaviruses Therapeutics and Interventions, MESH: Interferon alpha-2, 80 and over, 3202 Clinical Sciences, Lung, Asymptomatic Infections, MESH: Immunoglobulin G, Aged, 80 and over, MESH: Middle Aged, COVID Clinicians, MESH: Case-Control Studies, MESH: Critical Illness, Interferon Type I, Pneumonia & Influenza, Science & Technology - Other Topics, Medicine, Human, MESH: Pandemics, [SDV.IMM] Life Sciences [q-bio]/Immunology, Medicina, Critical Illness, Pneumonia, Viral, 610, Interferon alpha-2, Autoimmune Disease, HGID Lab, Betacoronavirus, anzsrc-for: 32 Biomedical and Clinical Sciences, Clinical Research, 616, Humans, MESH: SARS-CoV-2, COVID Human Genetic Effort, Aged, Autoantibodies, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, Science & Technology, Betacoronaviru, MESH: Antibodies, CYTOKINES, MESH: Adult, Pneumonia, Antibodies, Neutralizing, COVID-STORM Clinicians, Case-Control Studies, NIAID-USUHS Immune Response to COVID Group, MESH: Female, MESH: Interferon Type I, Coronaviruses, MESH: Coronavirus Infections, CHRONIC MUCOCUTANEOUS CANDIDIASIS, [SDV.GEN] Life Sciences [q-bio]/Genetics, Settore MED/03 - GENETICA MEDICA, CoV-Contact Cohort, Medicine and Health Sciences, Asymptomatic Infection, MESH: Autoantibodies, MESH: COVID-19, Viral, Imagine COVID Group, Amsterdam UMC Covid-19 Biobank, Neutralizing, Research Articles, MESH: Aged, Multidisciplinary, 3 Good Health and Well Being, Middle Aged, Coronaviruses Disparities and At-Risk Populations, Autoantibodie, Multidisciplinary Sciences, Infectious Diseases, Milieu Intérieur Consortium, Critical Illne, MESH: Betacoronavirus, [SDV.IMM]Life Sciences [q-bio]/Immunology, anzsrc-for: 3202 Clinical Sciences, Female, Case-Control Studie, Coronavirus Infections, Sciences exactes et naturelles, INTERFERON, Adult, MESH: Pneumonia, General Science & Technology, PROTEINS, French COVID Cohort Study Group, MESH: Asymptomatic Infections, Adult; Aged; Aged, 80 and over; Antibodies, Neutralizing; Asymptomatic Infections; Autoantibodies; Betacoronavirus; COVID-19; Case-Control Studies; Coronavirus Infections; Critical Illness; Female; Humans; Immunoglobulin G; Interferon Type I; Interferon alpha-2; Male; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2, Antibodies, Pandemics, Pandemic, Coronavirus Infection, SARS-CoV-2, COVID-19, GAMMA, MESH: Male, Emerging Infectious Diseases, Immunoglobulin G, ANTIBODIES

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	2K
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 0.01%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 0.1%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 0.01%